Search research articles
Contact Us
Filters
Showing results (51-60 of 75) with videos related to
Page
of 8
Sort By:
The Oncologist
|
April 1, 2021
Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies
Andrew J Wiele, Tharakeswara K Bathala, Andrew W Hahn, et al.
International Journal of Clinical Oncology
|
December 29, 2023
Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma
Hideki Goto, Satoshi Ito, Masahiro Kizaki, et al.
Translational Oncology
|
September 1, 2023
Evaluation of a semi-automated approach for FDG PET image analysis for routine clinical application in patients with multiple myeloma
Tyler J Wellman, Sarah R Mudd, Kelly N Godby, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 13, 2021
Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14)
Nizar J Bahlis, Rachid Baz, Simon J Harrison, et al.
European Urology Oncology
|
July 6, 2019
Temsirolimus versus Pazopanib (TemPa) in Patients with Advanced Clear-cell Renal Cell Carcinoma and Poor-risk Features: A Randomized Phase II Trial
Nizar M Tannir, Pavlos Msaouel, Jeremy A Ross, et al.
The Lancet. Haematology
|
June 30, 2025
Venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed or refractory multiple myeloma (BELLINI): final overall survival results from a randomised, phase 3 study
Shaji K Kumar, Simon J Harrison, Michele Cavo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 27, 2022
A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma
Anita D'Souza, Nina Shah, Cesar Rodriguez, et al.
American Journal of Hematology
|
November 15, 2021
Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapy
Relja Popovic, Fengjiao Dunbar, Charles Lu, et al.
Blood Advances
|
September 1, 2021
Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma
Luciano J Costa, Faith E Davies, Gregory P Monohan, et al.
Future Oncology (London, England)
|
March 30, 2018
Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignancies
Andrew E Place, Kelly Goldsmith, Jean-Pierre Bourquin, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 75) with videos related to
Sort By:
Page
of 8
The Oncologist
|
April 1, 2021
Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies
Andrew J Wiele, Tharakeswara K Bathala, Andrew W Hahn, et al.
International Journal of Clinical Oncology
|
December 29, 2023
Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma
Hideki Goto, Satoshi Ito, Masahiro Kizaki, et al.
Translational Oncology
|
September 1, 2023
Evaluation of a semi-automated approach for FDG PET image analysis for routine clinical application in patients with multiple myeloma
Tyler J Wellman, Sarah R Mudd, Kelly N Godby, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 13, 2021
Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14)
Nizar J Bahlis, Rachid Baz, Simon J Harrison, et al.
European Urology Oncology
|
July 6, 2019
Temsirolimus versus Pazopanib (TemPa) in Patients with Advanced Clear-cell Renal Cell Carcinoma and Poor-risk Features: A Randomized Phase II Trial
Nizar M Tannir, Pavlos Msaouel, Jeremy A Ross, et al.
The Lancet. Haematology
|
June 30, 2025
Venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed or refractory multiple myeloma (BELLINI): final overall survival results from a randomised, phase 3 study
Shaji K Kumar, Simon J Harrison, Michele Cavo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 27, 2022
A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma
Anita D'Souza, Nina Shah, Cesar Rodriguez, et al.
American Journal of Hematology
|
November 15, 2021
Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapy
Relja Popovic, Fengjiao Dunbar, Charles Lu, et al.
Blood Advances
|
September 1, 2021
Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma
Luciano J Costa, Faith E Davies, Gregory P Monohan, et al.
Future Oncology (London, England)
|
March 30, 2018
Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignancies
Andrew E Place, Kelly Goldsmith, Jean-Pierre Bourquin, et al.
Page
of 8